Beth Israel Deaconess Medical Center, Harvard Medical School, Cambridge, MA, USA.
Breast Cancer (Dove Med Press). 2010 Jun 21;2:37-44. doi: 10.2147/bctt.s6511.
Angiogenesis inhibitors may provide a new approach to the treatment of metastatic breast cancer. Bevacizumab is a monoclonal antibody against pathologic angiogenesis. A pivotal study (ECOG 2100) showed that bevacizumab in combination with paclitaxel increased progression-free survival for patients with metastatic breast cancer by 6 months. Subsequently, several clinical trials have shown that the combination of bevacizumab with a taxane can improve disease-free survival but does not prolong overall survival. While generally well tolerated, bevacizumab is potentially toxic for some patients who develop hypertension, proteinuria, bleeding, impaired wound healing, bowel perforation or thromboembolic events. Here, we review the current evidence for the use of bevacizumab in breast cancer and ongoing studies that address the questions of how to optimize regimens and schedules for the use of anti-angiogenic agents and the identification of those patients who would benefit the most from treatment with regimens that include antiangiogenic therapy.
血管生成抑制剂可能为转移性乳腺癌的治疗提供新方法。贝伐珠单抗是一种针对病理性血管生成的单克隆抗体。一项关键性研究（ECOG 2100）表明，贝伐珠单抗联合紫杉醇可使转移性乳腺癌患者的无进展生存期延长 6 个月。随后，多项临床试验表明，贝伐珠单抗联合紫杉烷类药物可改善无病生存期，但不能延长总生存期。贝伐珠单抗通常具有良好的耐受性，但某些患者可能出现毒性反应，如高血压、蛋白尿、出血、伤口愈合不良、肠穿孔或血栓栓塞事件。在此，我们对贝伐珠单抗在乳腺癌中的应用进行综述，并探讨了如何优化抗血管生成药物的治疗方案和时间表，以及确定哪些患者最受益于包含抗血管生成治疗的方案。
